AI Article Synopsis
Article Abstract
SRI 62-834, an analog of the antitumor agent ET-18-OCH3 in which the oxygen atom at carbon atom 2 has been incorporated into a five-membered heterocycle, has been prepared and evaluated as an antitumor agent. The compound exhibited good cytotoxicity in vitro against a variety of tumor cell lines and was as effective as ET-18-OCH3 given orally in the mouse Meth A sarcoma model. SRI 62-834 was shown to be an inhibitor of platelet-derived growth factor (PDGF), possibly at the receptor level, and platelet-activating factor (PAF) at the receptor level.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02535549 | DOI Listing |
Publication Analysis
Top Keywords
sri 62-834
12
antitumor agent
8
receptor level
8
antitumor activity
4
activity sri
4
62-834 cyclic
4
cyclic ether
4
ether analog
4
analog et-18-och3
4
et-18-och3 sri
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!